Aurora Financial Journalargenx SE (ARGX)
NASDAQ · Health care · Biological Products, (No Diagnostic Substances) · Financial statements, TTM figures and earnings dates
In fiscal year 2025 (ended December 31, 2025), argenx SE reported revenue of $4.15B and net income of $1.29B. Annual financial statements are available for fiscal years 2018 to 2025, taken from the company's filings with the SEC.
Open interactive financials →Key financials
| USD | FY2025 2025-12-31 | FY2024 2024-12-31 | FY2023 2023-12-31 | FY2022 2022-12-31 | FY2021 2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.15B | $2.19B | $35.5M | $10.0M | $497.3M |
| Gross profit | $3.70B | $1.96B | – | – | – |
| Operating income | $1.05B | −$21.7M | −$425.0M | −$720.3M | −$348.7M |
| Net income | $1.29B | $833.0M | −$295.1M | −$709.6M | −$408.3M |
| Diluted EPS | $19.57 | $12.78 | −$5.16 | −$13.05 | −$7.99 |
| Cash flow | |||||
| Operating cash flow | $685.2M | −$82.7M | −$420.3M | −$862.8M | −$606.8M |
| Capital expenditure | $6.2M | $1.8M | $812.0K | $837.0K | $3.6M |
| Free cash flow | $679.0M | −$84.5M | −$421.1M | −$863.6M | −$610.4M |
| Balance sheet | |||||
| Cash and equivalents | $3.49B | $1.50B | $2.05B | $800.7M | $1.33B |
| Total assets | $8.68B | $6.20B | $4.54B | $3.13B | $2.85B |
| Total liabilities | $1.36B | $704.2M | $445.0M | $320.6M | $316.1M |
| Total debt | – | – | $7.2M | – | – |
| Shareholders' equity | $7.32B | $5.50B | $4.10B | $2.81B | $2.53B |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in USD as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full ARGX page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open ARGX financials →